# Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS

> **NIH NIH UG1** · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $186,595

## Abstract

PROJECT SUMMARY
Allogeneic hematopoietic cell transplantation (HCT) is an essential therapeutic procedure used to enhance the outcome of
patients with acute myeloid leukemia (AML) and myelodysplasia (MDS). Recent advances in alternative donor
transplantation and supportive care have allowed for a greater number of older adults and those with co-morbidities to
pursue potentially curative transplant procedures. In addition, the emerging era of targeted therapy allows for the
development of novel disease remission induction regimens as well as transplant conditioning regimens that can enhance
outcomes. However, relapse after allogeneic HCT remains a major barrier to successful outcomes, with recent data
suggesting that up to 50% of allogeneic HCT failure and mortality relate to persistence or relapse of underlying disease.
Recent advances in the detection of minimal residual disease (MRD) have enhanced the capacity of identifying some
patients at risk of relapse after HCT. Using information obtained by cytogenetics, fluorescence in situ hybridization (FISH)
and genomics, successful outcomes can still be achieved in a subset of myeloid malignancy patients transplanted in the
setting of morphologically active or MRD-detectable disease at the time of transplant. This proposal is a pilot study to
determine whether augmented genomic MRD assessment both before and after transplant for myeloid malignancies can be
used to guide clinical investigators into offering post-HCT therapy. In so doing we hope to establish the importance of both
pre- and post-HCT MRD and to begin to explore novel interventions for post-HCT MRD using a variety of cellular and/or
pharmacologic-targeted approaches.

## Key facts

- **NIH application ID:** 10183299
- **Project number:** 5UG1HL138658-05
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** RICHARD Thomas MAZIARZ
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $186,595
- **Award type:** 5
- **Project period:** 2017-07-27 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10183299

## Citation

> US National Institutes of Health, RePORTER application 10183299, Novel Strategies for Assessing and Optimizing Therapy for Minimal Residual Disease after Allogeneic Transplantation for AML and MDS (5UG1HL138658-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10183299. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*